169 related articles for article (PubMed ID: 10428757)
1. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).
Kooby DA; Carew JF; Halterman MW; Mack JE; Bertino JR; Blumgart LH; Federoff HJ; Fong Y
FASEB J; 1999 Aug; 13(11):1325-34. PubMed ID: 10428757
[TBL] [Abstract][Full Text] [Related]
2. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases.
Reinblatt M; Pin RH; Federoff HJ; Fong Y
Ann Surg; 2004 Jun; 239(6):892-9; discussion 899-902. PubMed ID: 15166969
[TBL] [Abstract][Full Text] [Related]
3. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
[TBL] [Abstract][Full Text] [Related]
4. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).
Carew JF; Kooby DA; Halterman MW; Federoff HJ; Fong Y
Hum Gene Ther; 1999 Jul; 10(10):1599-606. PubMed ID: 10428205
[TBL] [Abstract][Full Text] [Related]
5. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
6. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
Stanziale SF; Petrowsky H; Joe JK; Roberts GD; Zager JS; Gusani NJ; Ben-Porat L; Gonen M; Fong Y
Surgery; 2002 Aug; 132(2):353-9. PubMed ID: 12219034
[TBL] [Abstract][Full Text] [Related]
7. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
8. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
Blank SV; Rubin SC; Coukos G; Amin KM; Albelda SM; Molnar-Kimber KL
Hum Gene Ther; 2002 Mar; 13(5):627-39. PubMed ID: 11916486
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer.
Bennett JJ; Kooby DA; Delman K; McAuliffe P; Halterman MW; Federoff H; Fong Y
J Mol Med (Berl); 2000; 78(3):166-74. PubMed ID: 10868479
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.
Toda M; Rabkin SD; Martuza RL
Hum Gene Ther; 1998 Oct; 9(15):2177-85. PubMed ID: 9794202
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.
Oyama M; Ohigashi T; Hoshi M; Murai M; Uyemura K; Yazaki T
Jpn J Cancer Res; 2000 Dec; 91(12):1339-44. PubMed ID: 11123435
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses.
McAuliffe PF; Jarnagin WR; Johnson P; Delman KA; Federoff H; Fong Y
J Gastrointest Surg; 2000; 4(6):580-8. PubMed ID: 11307092
[TBL] [Abstract][Full Text] [Related]
14. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro.
Lee JH; Federoff HJ; Schoeniger LO
J Gastrointest Surg; 1999; 3(2):127-31; discussion 132-3. PubMed ID: 10457334
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Todo T; Rabkin SD; Chahlavi A; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2869-78. PubMed ID: 10584932
[TBL] [Abstract][Full Text] [Related]
16. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer.
Endo T; Toda M; Watanabe M; Iizuka Y; Kubota T; Kitajima M; Kawakami Y
Cancer Gene Ther; 2002 Feb; 9(2):142-8. PubMed ID: 11857031
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
Huszthy PC; Goplen D; Thorsen F; Immervoll H; Wang J; Gutermann A; Miletic H; Bjerkvig R
Clin Cancer Res; 2008 Mar; 14(5):1571-80. PubMed ID: 18316582
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
Nakano K; Todo T; Chijiiwa K; Tanaka M
Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
[TBL] [Abstract][Full Text] [Related]
19. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes.
Carew JF; Kooby DA; Halterman MW; Kim SH; Federoff HJ; Fong Y
Mol Ther; 2001 Sep; 4(3):250-6. PubMed ID: 11545616
[TBL] [Abstract][Full Text] [Related]
20. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.
Jorgensen TJ; Katz S; Wittmack EK; Varghese S; Todo T; Rabkin SD; Martuza RL
Neoplasia; 2001; 3(5):451-6. PubMed ID: 11687957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
